

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete If Known</b>	
				Application Number	10/553,108
				Filing Date	
				First Named Inventor	Nobuo Mochizuki
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	1	of	2	Attorney Docket Number	20241/0203481-USO

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>3</sup>
		Country Code <sup>3</sup> -Number-Kind Code <sup>2</sup> (if known)				
M	BA	WO-01/14384-A1	03-01-2001	Takeda Chemical Industries, LTD.		✓
J	BB	CA-2382418-A1	03-01-2001	Takeda Chemical Industries, LTD.		
✓	BC	WO-01/68610-A1	09-20-2001	Taisho Pharmaceutical Co., LTD.		✓

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T <sup>2</sup>
W	CA	SCOTT JOHN W., et al., "6-Hydroxychroman-2-carboxylic Acids: Novel Antioxidants", Journal of the American oil Chemists' Society, Vol. 51, 1974, pp.200-203.				
	CB	CYRUS TILLMANN, et al., "Disruption of the 12/15-lipoxygenase gene diminishes atherosclerosis in apo E-deficient mice.", The Journal of Clinical Investigation, June 1999, Vol. 103, No. 11, pp.1597-1604.				
	CC	HARDER DR, et al., "Role of Cytochrome P-450 enzymes and metabolites of arachidonic acid in the control of vascular tone.", J Vasc Res., 1995, Vol 32(2), 79-92.				
	CD	McGiff JOHN C., et al., "20-HETE and the Kidney: Resolution of Old Problems and New Beginnings.", The American Physiological Society, 1999, R607-R623.				
	CE	ROMAN RICHARD J., "P-450 Metabolites of Arachidonic Acid in the Control of Cardiovascular Function.", The American Physiological Society, Physio Rev, 2002, Vol. 82, pp.131-185.				
	CF	ANDERSON RE, et al., "Free Radicals and Ocular Disease.", Adv Exp Med-Biol., 1994; 366: 73-86.				
	CG	NISHIGORI H., et al., "The Alteration of Lipid Peroxide in Glucocorticoid-induced cataract of developing chick embryos and the effect of ascorbic acid.", Curr Eye Res., 1986; 5(1), pp.37-40.				
	CH	HIRAMITSU T., et al., "Preventive Effect of Antioxidants on Lipid Peroxidation in the Retina.", Ophthalmic Res., 1991, 23(4); 196-203.				
	CI	Vitamin Information Center (Tokyo), VIC Newsletter, 105, 4, 2002.				
	CJ	J. Act. Oxyg. Free Rad., Vol 3, No.4, 1992.				
	CK	SOLBACH U., et al., "Imaging of Retinal Autofluorescence in Patients with Age-related Macular Degeneration.", Retina, 1997, 17(5), pp.385-389.				
✓	CL	C.D. FUNK, "Lipids and Lipid Metabolism", Biochimica et Biophysica Acta 1304, 1996, pp.65-				

W:202 410203		Date Considered	11/2/07
-----------------	--	--------------------	---------

Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/553,108
				Filing Date	
				First Named Inventor	Nobuo Mochizuki
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket Number	20241/0203481-US0

		84.	
<i>Net</i>	CM	HARDER DR, "Role of cytochrome P-450 enzymes and metabolites of arachidonic acid in the control of vascular tone.", J Vasc Res. 1995 Mar-Apr; 32(2):79-92.	
	CN	ANDERSON ROBERT E. et al., "Free Radicals and Ocular Disease", pp. 73-86	
	CO	NISHIGORI HIDEO, et al., "The Alteration of Lipid Peroxide in Glucocorticoid-induced Cataract of Developing Chick Embryos and the Effect of Absorbic Acid.", Vol. 5, No.1, 1986, pp.37-40.	
	CP	TRUSCOTT R.J.W., et al., "the state of sulphhydryl groups in normal and cataractous human lenses.", Exp. Eye Res., 1997, Vol. 25, 139-148.	
	CQ	HIRAMITSU TADAHISA, et al., "Preventive effect of antioxidants on lipid peroxidation in the retina.", Ophthalmic Res, 1991; Vol. 23; pp.196-203.	
<i>✓</i>	CR	SOLBACH UTA MD, et al., "Imaging of retinal autofluorescence in patients with age-related macular degeneration.", Retina, Journal of Retinal and Vitreous diseases, 1997, Vol. 17, No. 5, pp. 385-389.	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

W:202 4110203	<i>[Signature]</i>	Date Considered	11/2/07
------------------	--------------------	--------------------	---------

Substitute for form 1449A/B/PTO				Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				Application Number	Not Yet Assigned
				Filing Date	Concurrently Herewith
				First Named Inventor	Nobuo Mochizuki
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	1	of	2	Attorney Docket Number	20241/0203481-US0

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
WJ	AA*	US-6,342,516-B1	01-29-2002	Umeda et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
WJ	BA	WO-00/06550-A1	02-10-2000	Nippon Soda Co., Ltd.		✓
	BB	JP-61-044840-A	03-04-1986	Takeda Chem. Ind. Ltd.		✓
	BC	JP-01-104033-A	04-21-1989	Takeda Chem. Ind. Ltd.		✓
	BD	JP-02-121975-A	05-09-1990	Eisai Co., Ltd.		✓
	BE	EP-0 345 593-A1	12-13-1989	Takeda Chem. Ind. Ltd.		
	BF	EP-0 483 772-A1	05-06-1992	Takeda Chem. Ind. Ltd.		
	BG	WO-95/29163-A1	11-02-1995	Nippon Soda Co., Ltd.		✓
	BH	DE-3407505-A1	09-05-1985	Nattermann A & CIE		✓
	BI	JP-55-069567-A	05-26-1980	Eisai Co., Ltd.		✓
	BJ	EP-0 324 377-A2	07-19-1989	E.I. Du Pont De Nemours and Company		
	BK	EP-0 458 037-A1	11-27-1991	American Cyanamid Company		
	BL	JP-05-140142-A	06-08-1993	Takeda Chem. Ind. Ltd.		✓
	BM	WO-96/28437-A1	09-19-1996	Hoechst Marion Roussel, Inc.		✓
	BN	JP-06-228136-A	08-16-1994	Takeda Chem. Industries, Ltd.		✓
	BO	JP-02-076869-A	03-16-1990	Takeda Chem. Industries, Ltd.		✓
	BP	JP-2004-010513-A	01-15-2004	Taisho Pharmaceutical Co., Ltd.		✓
	BQ	WO-03/022821-A1	03-20-2003	Taisho Pharmaceutical Co., Ltd.		✓
	BR	JP-06-287139-A	10-11-1994	Takeda Chem. Ind. Ltd., Senju Pharmaceutical Co., Ltd.		✓
	BS	WO-00/07581-A2	02-17-2000	Sigma-Tau Healthscience S.P.A.		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	CA	International Search Report for PCT/JP2004/005237 mailed July 13, 2004.	
	CB	Patent Abstracts of Japan for JP61-044840 published March 4, 1986.	

WJ:202		Date Considered	
--------	--	-----------------	--

JC20 Rec'd PCT/PTO 1 3 OCT 2005

PTO/SB/08a/b (07-05)

Approved for use through 07/31/2008. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				Application Number	
				Filing Date	
				First Named Inventor	
				Art Unit	
				Examiner Name	
Sheet 2 of 2				Attorney Docket Number	
				20241/0203481-US0	

✓	CC	Patent Abstracts of Japan for JP01-104033 published April 21, 1989.	
	CD	Patent Abstracts of Japan for JP02-121975 published May 9, 1990.	
	CE	Patent Abstracts of Japan for JP55-069567 published May 26, 1980.	
	CF	Patent Abstracts of Japan for JP05-140142 published June 8, 1993.	
	CG	Patent Abstracts of Japan for JP06-228136 published August 16, 1994.	
	CH	Patent Abstracts of Japan for JP02-076869 published March 16, 1990.	
	CI	Patent Abstracts of Japan for JP2004-010513 published January 15, 2004.	
✓	CJ	Patent Abstracts of Japan for JP06-287139 published October 11, 1994.	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

W:1202 11/02/03		Date Considered	11/2/07
--------------------	--	-----------------	---------